INmune Bio, Inc.

INMB

US45782T1051

Biotechnology & Medical Research

Real-time Estimate Cboe BZX Other stock markets 18:21:13 02/07/2024 BST			5-day change	1st Jan Change
8.03 ^USD	-4.63%		+12.59%	-28.51%

06-27	INmune Bio, Inc. Completes Blinded Interim Analysis of Phase II Alzheimer's Disease Trial	CI
05-30	Sector Update: Health Care Stocks Higher in Afternoon Trading	MT

INmune Bio, Inc. Announces David Szymkowski to Step Down from Board of Directors

June 14, 2021 at 09:01 pm

INmune Bio, Inc. announced that David Szymkowski, Ph.D., Vice President of Preclinical Operations at Xencor, stepped down from INmune’s Board of Directors.

Latest news about INmune Bio, Inc.

INmune Bio, Inc. Completes Blinded Interim Analysis of Phase II Alzheimer's Disease Trial	06-27	CI
Sector Update: Health Care Stocks Higher in Afternoon Trading	05-30	MT
INmune Bio to Join Russell 3000 Index in July	05-30	MT
Earnings Flash (INMB) INMUNE BIO Reports Q1 Revenue $14,000	05-09	MT
Transcript : INmune Bio, Inc., Q1 2024 Earnings Call, May 09, 2024	05-09
INmune Bio, Inc. Reports Earnings Results for the First Quarter Ended March 31, 2024	05-09	CI
INmune Bio, Inc. Provides Update on Two Patients from the Phase 1b Alzheimer's Disease Trial	04-30	CI
INmune Bio Inc. Completes First Cohort and Initiates Second Cohort of Phase 1/2 Study of INKmune?? Natural Killer Cell Therapy in Patients with Metastatic Castration-Resistant Prostate Cancer	04-29	CI
Inmune Bio Inc. Announces 24-Month Stability Validation of Xpro? for Phase III Readiness and Commercial Supply Chain Modeling & Development of Novel Immunogenicity Assay	04-23	CI
INmune Bio Inc. Presents Data on INB03's Role as an Immune Check Point Modulator in the Treatment of High-Risk Breast Cancer at AACR 2024	04-08	CI
Transcript : INmune Bio, Inc., Q4 2023 Earnings Call, Mar 28, 2024	03-28
INmune Bio, Inc. Reports Earnings Results for the Full Year Ended December 31, 2023	03-28	CI
INmune Bio, Inc. Reports Significant EEG Improvement in Alzheimer's Patients Treated with XPro	03-05	CI
FDA Lifts Clinical Hold on INmune Bio Alzheimer's Program	01-30	DJ
Inmune Bio Announces FDA Removal of Clinical Hold for Alzheimer?S Disease Program	01-30	CI
ELEVAI Labs, Inc. Acquires Worldwide License Agreement for Proprietary Stem Cell Manufacturing Technology	01-16	CI
Elevai Labs, Inc. signed a license agreement to acquire a Worldwide License Agreement for Proprietary Stem Cell Manufacturing Technology from INmune Bio, Inc..	01-15	CI
INmune Bio, Inc. Announces First Patient Dosed in Phase 1/2 Study of INKmune in Patients with Metastatic Castration-Resistant Prostate Cancer	01-02	CI
Sector Update: Health Care Stocks Gain Premarket Tuesday	12-19	MT
Looming Inflation Data Stifle US Equity Futures Pre-Bell	12-19	MT
Sector Update: Health Care	12-19	MT
INmune Bio Shares Drop as Alzheimer's Treatment Study Remains on Hold	12-19	DJ
Top Premarket Decliners	12-19	MT
INmune Bio Alzheimer's Treatment Remains on Clinical Hold After FDA Requests Information; Shares Slump After Hours	12-18	MT
INmune Bio Alzheimer's Treatment Study to Remain on Clinical Hold	12-18	DJ

INmune Bio Inc. is a clinical-stage biotechnology company focused on developing treatments that target the innate immune system to fight disease. It has two therapeutic platforms: a Dominant-Negative Tumor Necrosis Factor Platform (DN-TNF, XPro, XPro1595 or pegipanermin) and a Natural Killer (NK or INKmune) platform. The DN-TNF product platform utilizes dominant-negative technology to selectively neutralize soluble TNF, a key driver of innate immune dysfunction and a mechanistic driver of many diseases. DN-TNF product candidates are in clinical trials to determine if they can treat cancer (INB03) Mild Alzheimer's disease, Mild Cognitive Impairment and treatment-resistant depression (XPro). The NK Cell Priming Platform includes INKmune developed to prime a patient's NK cells to eliminate minimal residual disease in patients with cancer. Its product platforms utilize a precision medicine approach for the treatment of hematologic and solid tumor malignancies, and chronic inflammation.

Sector

Biotechnology & Medical Research

Calendar

19/07/2024 - Annual General Meeting

More about the company

Income Statement Evolution

More financial data

Ratings for INmune Bio, Inc.

Trading Rating

Investor Rating

ESG Refinitiv

More Ratings

Analysts' Consensus

Sell

Buy

Mean consensus

BUY

Number of Analysts

Last Close Price

8.42 USD

Average target price

19.67 USD

Spread / Average Target

+133.57%

Consensus

EPS Revisions

Estimates Revisions

Quarterly earnings - Rate of surprise

Company calendar

Sector Bio Therapeutic Drugs

	1st Jan change	Capi.
INMUNE BIO, INC.	-28.51%	167M
VERTEX PHARMACEUTICALS INCORPORATED	+16.35%	122B
REGENERON PHARMACEUTICALS, INC.	+17.43%	114B
ARGENX SE	+19.62%	25.71B
BIONTECH SE	-25.86%	19.02B
GENMAB A/S	-20.21%	15.83B
BEIGENE, LTD.	-19.83%	15.32B
WUXI APPTEC CO., LTD.	-47.37%	14.88B
SAREPTA THERAPEUTICS, INC.	+59.47%	14.82B
NEUROCRINE BIOSCIENCES, INC.	+4.80%	14.1B

Bio Therapeutic Drugs

INmune Bio, Inc.

Equities

INMB

US45782T1051

Biotechnology & Medical Research

INmune Bio, Inc. Announces David Szymkowski to Step Down from Board of Directors

Latest news about INmune Bio, Inc.

Chart INmune Bio, Inc.

Company Profile

Income Statement Evolution

Ratings for INmune Bio, Inc.

Analysts' Consensus

EPS Revisions

Quarterly earnings - Rate of surprise

Sector Bio Therapeutic Drugs